SHEUNG YUE GP(01633) issues profit warning, expecting annual net loss to increase by approximately HK$23.90 million on a year-on-year basis.
Shangyu Group (01633) announced that the Group is expecting to incur a net loss of approximately HK$23.9 million for the year ending on March 31, 2026, compared to a net loss of approximately HK$9.7 million for the year ending on March 31, 2025. According to the information currently available to the board of directors, the board believes that the net loss is mainly due to: (i) decrease in the Group's revenue; (ii) overall decrease in the gross profit margin of projects undertaken by the Group; (iii) expected credit loss provisions on financial assets; and (iv) impairment losses on right-of-use assets acquired by the Group.
SHEUNG YUE GP (01633) announces that the Group is expected to incur a net loss of approximately 23.9 million Hong Kong dollars for the year ending on March 31, 2026, compared to a net loss of approximately 9.7 million Hong Kong dollars for the year ending on March 31, 2025. Based on the information currently available to the board of directors, the board believes that the net loss is mainly attributable to:
(i) Decrease in the Group's revenue;
(ii) Decrease in overall gross profit margin of projects undertaken by the Group;
(iii) Expected credit loss provision for financial assets; and
(iv) Impairment losses on right-of-use assets acquired by the Group.
Related Articles
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
RECOMMEND
